drugset / Trial / NCT07609875

A Phase I Single and Multiple Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of HS-10522 in Healthy Chinese Participants and Chinese Participants With Mild Hypertension

NCT07609875 ↗

Phase 1 Not yet recruiting 88 enrolled Jiangsu Hansoh Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple oral doses of HS-10522 in healthy Chinese participants and Chinese participants with mild hypertension.

Timeline

Start
2026-06-01
Primary completion
2027-01-20
Completion
2027-02-03

Drugs

EvaluationDrugModalityDoseRoute
Subject HS-10522 Unknown — Oral

Indications